STOCK TITAN
  1. Home
  2. Sec-filings
  3. SCTX
  4. [Form 4] Scribe Therapeutics, Inc. Insider Trading Activity

Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. reported that President, CEO and Chairman Benjamin L. Oakes received three option awards for its common stock. On March 13, 2026, he was granted 12,969 options with a $19.13 exercise price, which are fully vested. On July 23, 2026, he received a time-based option for 264,784 shares at $15.00 per share, vesting in equal monthly installments over four years starting August 23, 2026, and a performance-based option for 429,599 shares at $15.00 per share, eligible to vest upon specified market-based performance criteria during a period from July 23, 2026 to July 23, 2029. The July 2026 grants expire on July 22, 2036, and the March 2026 grant expires on March 12, 2036.

Positive

  • None.

Negative

  • None.
Insider Oakes Benjamin L.
Role President, CEO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F3 264,784 $0.00 $0.00
Grant/Award Performance-based Stock Option (Right to Buy) F4 429,599 $0.00 $0.00
Grant/Award Stock Option (Right to Buy) F1, F2 12,969 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 277,753 shares (Direct); Performance-based Stock Option (Right to Buy) — 429,599 shares (Direct)
Footnotes (4)
  1. F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  2. F2. The option is fully vested.
  3. F3. The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  4. F4. The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
March 2026 option shares 12,969 shares Stock option grant on March 13, 2026 to Benjamin L. Oakes
March 2026 exercise price $19.13 per share Exercise price for 12,969-share option expiring March 12, 2036
Time-based July 2026 option 264,784 shares at $15.00 Monthly vesting over four years starting August 23, 2026
Performance-based July 2026 option 429,599 shares at $15.00 Eligible to vest based on market criteria from July 23, 2026 to July 23, 2029
July 2026 grants expiration July 22, 2036 Expiration date for both July 23, 2026 option awards
Rule 16a-2(a) regulatory
"reported herein pursuant to Rule 16a-2(a)."
market-based performance criteria financial
"eligible to vest upon the achievement of certain market-based performance criteria"
initial public offering financial
"in connection with the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
performance period financial
"during a performance period beginning on July 23, 2026 and ending on July 23, 2029"
The performance period is the specific time span over which an investment’s results, an employee’s targets, or a fund’s returns are measured and judged. It matters to investors because the length and start/end of that window determine which gains or losses count toward performance fees, bonus payouts, or benchmark comparisons—much like timing a race decides who wins, the chosen period can change whether results look strong or weak.

FAQ

What option grants did Scribe Therapeutics (SCTX) CEO Benjamin Oakes receive in March 2026?
Benjamin Oakes received 12,969 stock options on March 13, 2026, with an exercise price of $19.13 per share. According to the disclosure, this option is fully vested and expires on March 12, 2036.

What time-based stock options were granted to the SCTX CEO on July 23, 2026?
On July 23, 2026, Benjamin Oakes was granted 264,784 stock options with a $15.00 exercise price. These options vest as to 1/48 of the shares monthly over four years, starting on August 23, 2026, subject to continued service.

What performance-based stock options did Scribe Therapeutics (SCTX) grant its CEO in July 2026?
Scribe Therapeutics granted Benjamin Oakes 429,599 performance-based stock options on July 23, 2026, with a $15.00 exercise price. They may vest upon achieving market-based performance criteria during a period from July 23, 2026 to July 23, 2029.

When do Benjamin Oakes’ new Scribe Therapeutics (SCTX) option awards expire?
The March 13, 2026 option grant for 12,969 shares expires on March 12, 2036. Both the time-based and performance-based July 23, 2026 option grants expire on July 22, 2036, as disclosed in the filing.

How do the vesting terms differ for Scribe Therapeutics (SCTX) CEO’s July 2026 option grants?
The 264,784-share July 2026 option vests monthly over four years, starting August 23, 2026. The 429,599-share option is performance-based, eligible to vest upon market criteria met between July 23, 2026 and July 23, 2029, with continued service required.

What is the significance of Rule 16a-2(a) in the Scribe Therapeutics (SCTX) Form 4?
One option grant is described as occurring before the company registered equity securities for its IPO and is reported under Rule 16a-2(a). This rule addresses how certain pre-registration transactions are reported once a company becomes subject to Section 16.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oakes Benjamin L.
(Last)(First)(Middle)
C/O SCRIBE THERAPEUTICS INC.
1150 MARINA VILLAGE PARKWAY
(Street)
ALAMEDA CALIFORNIA 94501
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)XOther (specify below)
President, CEOChairman of the Board
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$19.1303/13/2026(1)A12,969 (2)03/12/2036Common Stock12,969$012,969D
Stock Option (Right to Buy)$1507/23/2026A264,784 (3)07/22/2036Common Stock264,784$0264,784D
Performance-based Stock Option (Right to Buy)$1507/23/2026A429,599 (4)07/22/2036Common Stock429,599$0429,599D
Explanation of Responses:
1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
2. The option is fully vested.
3. The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ David L. Parrot, Attorney-in-Fact07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR